Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Alkermes plc
  6. News
  7. Summary
    ALKS   IE00B56GVS15


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Alkermes : Announces 2021 Alkermes Inspiration Grants Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer

05/14/2021 | 07:26am EDT

DUBLIN - Alkermes plc (Nasdaq: ALKS) announced that the company will begin accepting applications for its Alkermes Inspiration Grants program beginning on May 20, 2021. Now in its fifth year, this competitive grants program will provide up to a total of $500,000 in grants to assist nonprofit organizations in their work to address the needs of people living with addiction, serious mental illness or cancer. This program will prioritize funding for proposals that are designed to address the needs of historically under-resourced or underrepresented communities.

'Our grant programs serve an important purpose in helping drive positive changes in the healthcare system. These programs complement our central mission of developing innovative medicines designed to address unmet patient needs,' said Richard Pops, Chief Executive Officer of Alkermes. 'The Alkermes Inspiration Grants program seeks to support people living with highly-stigmatized diseases, who often face unique challenges due to longstanding and widespread health disparities. In its fifth year, this program will continue to fund innovative programs that seek to support the physical, social and emotional needs of people living with addiction, serious mental illness and cancer.'

Alkermes is seeking to support programs with a broad reach across the U.S. that have the potential to lead to sustained impact. Submissions will be evaluated based on the set of criteria outlined in the request for proposals, including a focus on people living with mental illness, substance use disorders and/or cancer; clearly defined needs, objectives, activity format, mode of delivery and intended audience; and relevance to historically under-resourced or underrepresented communities. Grant recipients will be selected by Alkermes. Eligible U.S. 501(3) nonprofit organizations may submit a grant application by visiting https://www.alkermes.com/responsibility. The 2021 application period will run from May 20, 2021 through June 17, 2021.

For more information on the Alkermes Inspiration Grants program, including the application, submission instructions and evaluation criteria, please visit https://www.alkermes.com/responsibility.

About Alkermes plc

Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

ALKERMES INSPIRATION GRANTS is a registered service mark of Alkermes, Inc.




Alex Braun

T: +1 781 296 9493


Gretchen Murphy

T: +1 781 609 6419

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about ALKERMES PLC
06/14ALKERMESá : Stock Option and Incentive Plan, as amended (Form 8-K)
06/14ALKERMES PLC.á : Change in Directors or Principal Officers, Submission of Matter..
06/07ALKERMESá : Presents New Data on Nemvaleukin Alfa at 2021 American Society of Cl..
06/05ALKERMESá : ALKS FINAL_ASCO21 Nemva IR Call 6.4.21 9.00am.pdf
06/04ALKERMESá : Presents Nemvaleukin Alfa Data at American Society of Clinical Oncol..
06/03ALKERMESá : to Take Part in the Goldman Sachs Annual Global Healthcare Conferenc..
06/02ALKERMESá : Announces FDA Approval of LYBALVI for the Treatment of Schizophrenia..
06/02ALKERMESá : HC Wainwright Adjusts Alkermes' Price Target to $25 From $24, Keeps ..
06/01SECTOR UPDATE : Health Care Stocks Trying to Make Gains Ahead of Tuesday Opener
06/01SECTOR UPDATE : Health Care
More news
Financials (USD)
Sales 2021 1 142 M - -
Net income 2021 -105 M - -
Net cash 2021 360 M - -
P/E ratio 2021 -38,0x
Yield 2021 -
Capitalization 3 918 M 3 918 M -
EV / Sales 2021 3,12x
EV / Sales 2022 2,80x
Nbr of Employees 2 245
Free-Float 96,7%
Duration : Period :
Alkermes plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALKERMES PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 12
Average target price 22,45 $
Last Close Price 24,42 $
Spread / Highest target 18,8%
Spread / Average Target -8,05%
Spread / Lowest Target -34,5%
EPS Revisions
Managers and Directors
Richard F. Pops Chairman & Chief Executive Officer
Iain Michael Brown Senior VP, Chief Financial & Accounting Officer
Craig C. Hopkinson Chief Medical Officer & EVP-Research & Development
Thomas Harvey Chief Information Officer & Senior VP-IT
Sondra Smyrnios Senior Vice President-Clinical Operations
Sector and Competitors
1st jan.Capitalization (M$)
ALKERMES PLC22.41%3 918
MODERNA, INC.90.67%81 297
LONZA GROUP LTD15.68%53 313
CELLTRION, INC.-24.79%32 426
SEAGEN INC.-10.75%27 835